Marksans Pharma Ltd - 524404 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Please find enclosed herewith a Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th June, 2019 received from Bigshare Services Private Limited, Registrar and Share Transfer Agent of the Company. You are requested to note the above in your records. Marksans Pharma Ltd - 524404 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Please find enclosed herewith a Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th June, 2019 received from Bigshare Services Private Limited, Registrar and Share Transfer Agent of the Company. You are requested to note the above in your records. MARKSANS PHARMA LTD. - 524404 - Statement Of Investor Complaints For The Quarter Ended June 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0110 Name of the Signatory :- HARSHAVARDHAN PANIGRAHIDesignation :- Company Secretary and Compliance Officer Marksans Pharma Ltd - 524404 - Announcement under Regulation 30 (LODR)-Change in Directorate
Appointment of Mr. Abhinna Sundar Mohanty as Independent Director Dear Sir, This is to inform you that the Board of Directors of the Company, at its meeting held today, i.e. 11th July, 2019, has appointed Mr. Abhinna Sundar Mohanty (DIN: 0007995) as an Independent Director. Mr. Abhinna Sundar Mohanty is M.Sc. in Mathematics from Revenshaw University, Odisha. He has 39 years of experience in the pharmaceutical industry. He started his career with Alembic and went on to build his career through every cadre in sales and marketing department of pharma industry. During his career, he was engaged in sales, marketing, business development and business strategy for over 27 years in pharma industry. He was instrumental in globalising branded business of Pharma sector in most part of the world. Mr. Abhinna Sundar Mohanty is not related to any Directors of the Company in any manner. You are requested to note the above in your records. Marksans Pharma Ltd - 524404 - Closure of Trading Window
In terms of the Company's Code of Conduct to Regulate, Monitor and Report Trading by designated persons framed pursuant to SEBI (Prohibition of Insider Trading)(Amendment) Regulations, 2018, the trading window for dealing in the securities of Marksans Pharma Limited (the Company) for the insiders of the Company will remain closed with effect from Monday, 1st July, 2019 till 48 hours after the declaration of financial results for the quarter ended 30th June, 2019. The date of declaration of financial results will be intimated separately in due course of time. Designated Persons, Employees and other insiders of the Company and/or their immediate relatives shall not trade in the securities of the Company during the aforesaid period of closure of trading window. You are requested to note the above in your records. Marksans Pharma Ltd - 524404 - Receipt Of Establishment Inspection Report (EIR) From The US FDA
Sub: Receipt of Establishment Inspection Report (EIR) from the US FDA Dear Sirs, We are pleased to announce receipt of Establishment Inspection Report (EIR) from the US FDA in respect of inspection of the Company's Goa facility carried out from 25th February to 6th March 2019. This is for your information and records. Marksans Pharma Ltd - 524404 - Board recommends Dividend
Marksans Pharma Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 29, 2019, inter alia, has recommended dividend of Rs. 0.05 (Rupees Zero and Paise Five) i.e. 5% per equity share of Re. 1/- each face value for the financial year ended March 31, 2019, subject to approval of the shareholders in the ensuing Annual GeneralMeeting. Marksans Pharma Ltd - 524404 - Outcome of Board Meeting
Sub: Outcome of Board Meeting Dear Sir, This is to inform you that the Board of Directors of the Company has, at its meeting held today i.e. Wednesday, 29th May, 2019 at Mumbai, recommended dividend of Rs. 0.05 (Rupees Zero and Paise Five) i.e. 5% per equity share of Re. 1/- each face value for the financial year ended 31st March, 2019, subject to approval of the shareholders in the ensuing Annual General Meeting. Marksans Pharma Ltd - 524404 - News Release Dated 29Th May, 2019 Of The Company.
Sub: News Release Dear Sir, Enclosed herewith kindly find a News Release dated 29th May, 2019 of the Company. You are requested to note the above in your records. Marksans Pharma Ltd - 524404 - Audited Annual Financial Results For The Financial Year Ended 31St March, 2019 And Auditors Report Thereon.
Sub: Audited Annual Financial Results for the financial year ended 31st March, 2019 and Auditors Report thereon. Dear Sir, In terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, kindly find enclosed herewith Audited Annual Financial Results for the financial year ended 31st March, 2019 (both Standalone and Consolidated) approved by the Board of Directors at its meeting held today i.e. 29th May, 2019 along with Auditors Report thereon. The meeting commenced at 11:00 a.m. and concluded at 01:00 p.m. In this connection, we hereby certify that the Auditors have given their reports on the Audited Annual Financial Results for the financial year ended 31st March, 2019 (both Standalone and Consolidated) with unmodified opinion. You are requested to note the above in your records.